Peanut Market
Feb 04, 2020
First-ever Peanut allergy treatment; Dinutuximab misses primary endpoint; Insmed’s shares Soares
The US FDA has given its recommendation to the Aimmune Therapeutics’ drug, Palforzia, the first-ever treatment for Peanut Allergy. Palforzia is an oral immunotherapy, set to address the unmet needs in the Peanut market, reducing the incidence and severity of allergic reactions, including anaphylaxis, which may ...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
